{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:31:57Z","timestamp":1791657117445,"version":"4.3.4"},"reference-count":36,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Fitusiran is an investigational small interfering RNA therapeutic that targets antithrombin (AT) to rebalance hemostasis in people with hemophilia. Here, we present the results of a completed phase 2 open-label extension study, which evaluated the long-term safety and efficacy of fitusiran in participants with moderate or severe hemophilia A or B, with or without inhibitors. Male participants who had completed the phase 1 study (ClinicalTrials.gov identifier: NCT02035605) were enrolled. Participants received monthly subcutaneous fitusiran (50 or 80\u00a0mg) under the original dose regimen until a voluntary dosing pause in 2020, after which the AT-based dose regimen was introduced, targeting the recommended AT activity levels of 15% to 35%. Thirty-four participants (hemophilia A, n\u00a0=\u00a027; hemophilia B, n\u00a0=\u00a07) were enrolled in the phase 2 study and treated with fitusiran for a median exposure of 4.1 years. Adverse events reported on the original and the AT-based dose regimen were consistent with the identified risks of fitusiran. After implementation of the AT-based dose regimen, there were no thrombotic events, and a reduction in the incidence of elevated transaminases and biliary events was reported. The observed median annualized bleed rate (ABR) on the AT-based dose regimen (0.87) was comparable with the ABR under the original dose regimen (0.70). Furthermore, fitusiran prophylaxis was associated with improved health-related quality of life compared with baseline and provided successful hemostatic control during surgical procedures and invasive interventions. Overall, fitusiran was well tolerated, and effective bleeding control was maintained on an AT-based dose regimen. This trial was registered at www.clinicaltrials.gov as #NCT02554773.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013900","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T20:51:08Z","timestamp":1733518268000},"page":"1147-1158","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-2089","authenticated-orcid":false,"given":"Steven W.","family":"Pipe","sequence":"first","affiliation":[{"name":"1Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshko","family":"Lissitchkov","sequence":"additional","affiliation":[{"name":"2Clinic of Haematology, Specialized Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-6754","authenticated-orcid":false,"given":"Pencho","family":"Georgiev","sequence":"additional","affiliation":[{"name":"3Division of Hematology, University Multiprofile Hospital for Active Treatment \"Sveti Georgi\" and Medical University Plovdiv, Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-6241","authenticated-orcid":false,"given":"Sarah","family":"Mangles","sequence":"additional","affiliation":[{"name":"4Haemophilia, Haemostasis and Thrombosis Centre, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Hegemann","sequence":"additional","affiliation":[{"name":"5Hemophilia Comprehensive Care Center, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Trinchero","sequence":"additional","affiliation":[{"name":"6Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6690-8586","authenticated-orcid":false,"given":"Pratima","family":"Chowdary","sequence":"additional","affiliation":[{"name":"7Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Forbes","sequence":"additional","affiliation":[{"name":"8Haematology Department, Royal Cornwall Hospital, Cornwall, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqi","family":"Feng","sequence":"additional","affiliation":[{"name":"9Sanofi, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel A.","family":"Menapace","sequence":"additional","affiliation":[{"name":"10Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Kichou","sequence":"additional","affiliation":[{"name":"11Sanofi, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"Andersson","sequence":"additional","affiliation":[{"name":"10Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Demissie","sequence":"additional","affiliation":[{"name":"10Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-5379","authenticated-orcid":false,"given":"Margaret V.","family":"Ragni","sequence":"additional","affiliation":[{"name":"12Division Hematology\/Oncology, University of Pittsburgh, Pittsburgh, PA"},{"name":"13Hemophilia Center of Western Pennsylvania, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"9371","key":"2025032513471002200_bib1","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"2025032513471002200_bib2","first-page":"344","article-title":"Diagnosis and treatment of hemophilia","volume":"17","author":"Kizilocak","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"2025032513471002200_bib3","doi-asserted-by":"crossref","first-page":"100582","DOI":"10.1016\/j.blre.2019.05.006","article-title":"The central role of thrombin in bleeding disorders","volume":"38","author":"Negrier","year":"2019","journal-title":"Blood Rev"},{"issue":"1","key":"2025032513471002200_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2025032513471002200_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12929-021-00760-4","article-title":"Advances in the management of haemophilia: emerging treatments and their mechanisms","volume":"28","author":"Okaygoun","year":"2021","journal-title":"J\u00a0Biomed Sci"},{"issue":"4","key":"2025032513471002200_bib6","first-page":"39","article-title":"Outcome of clinical trials with new extended half-life FVIII\/IX concentrates","volume":"6","author":"Mancuso","year":"2017","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"2025032513471002200_bib7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"suppl 6","key":"2025032513471002200_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"21","key":"2025032513471002200_bib9","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2017-08-742312","article-title":"Novel approaches to hemophilia therapy: successes and challenges","volume":"130","author":"Arruda","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2025032513471002200_bib10","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/hae.14372","article-title":"Adoption of emicizumab (Hemlibra\u00ae) for hemophilia A in Europe: data from the 2020 European Association for Haemophilia and Allied Disorders survey","volume":"27","author":"Krumb","year":"2021","journal-title":"Haemophilia"},{"key":"2025032513471002200_bib11","unstructured":"Electronic medicines compendium\n          . Hemlibra summary of product characteristics. 2021. Accessed 3 January 2025. https:\/\/www.medicines.org.uk\/emc\/product\/9043\/smpc."},{"issue":"9","key":"2025032513471002200_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025032513471002200_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/hae.13877","article-title":"Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors","volume":"26","author":"Ebbert","year":"2020","journal-title":"Haemophilia"},{"issue":"5","key":"2025032513471002200_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2025032513471002200_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Hemophilia therapy: the future has begun","volume":"105","author":"Mannucci","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2025032513471002200_bib16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MOH.0000000000000364","article-title":"Targeting activated protein C to treat hemophilia","volume":"24","author":"Polderdijk","year":"2017","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"2025032513471002200_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/hematology.2021000253","article-title":"Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?","volume":"2021","author":"Ellsworth","year":"2021","journal-title":"Hematology"},{"issue":"5","key":"2025032513471002200_bib18","doi-asserted-by":"crossref","first-page":"e28934","DOI":"10.1002\/pbc.28934","article-title":"Novel treatments for hemophilia through rebalancing of the coagulation cascade","volume":"68","author":"Zhao","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2025032513471002200_bib19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40265-023-01912-6","article-title":"Concizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"9","key":"2025032513471002200_bib20","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14712598.2022.2002842","article-title":"Hemophilia A gene therapy: current and next-generation approaches","volume":"22","author":"Pipe","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"17-18","key":"2025032513471002200_bib21","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1089\/hum.2023.112","article-title":"Hemophilia gene therapy: the end of the beginning?","volume":"34","author":"De Wolf","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"9","key":"2025032513471002200_bib22","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025032513471002200_bib23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1056\/NEJMcibr1505657","article-title":"Targeting antithrombin to treat hemophilia","volume":"373","author":"Ragni","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025032513471002200_bib24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"issue":"6","key":"2025032513471002200_bib25","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort","volume":"19","author":"Pasi","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10386","key":"2025032513471002200_bib26","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"2025032513471002200_bib27","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"issue":"22","key":"2025032513471002200_bib28","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2023021864","article-title":"Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis (ATLAS-PPX)","volume":"143","author":"Kenet","year":"2024","journal-title":"Blood"},{"key":"2025032513471002200_bib29","author":"Negrier","year":"2021"},{"issue":"11","key":"2025032513471002200_bib30","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2025032513471002200_bib31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/hae.12642","article-title":"Interpreting important health-related quality of life change using the Haem-A-QoL","volume":"21","author":"Wyrwich","year":"2015","journal-title":"Haemophilia"},{"issue":"2","key":"2025032513471002200_bib32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.seminhematol.2007.02.004","article-title":"Epidemiology and risk factors for venous thrombosis","volume":"44","author":"Cushman","year":"2007","journal-title":"Semin Hematol"},{"key":"2025032513471002200_bib33","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.12491.1","article-title":"Emerging therapies for hemophilia: controversies and unanswered questions","volume":"7","author":"Arruda","year":"2018","journal-title":"F1000Res"},{"key":"2025032513471002200_bib34","first-page":"135","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B","volume":"9","author":"Machin","year":"2018","journal-title":"J\u00a0Blood Med"},{"key":"2025032513471002200_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.02.003","article-title":"Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics","volume":"203","author":"Lorenzer","year":"2015","journal-title":"J\u00a0Control Release"},{"key":"2025032513471002200_bib36","author":"Padda","year":"2023"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1147\/2357615\/blooda_adv-2024-013900-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1147\/2357615\/blooda_adv-2024-013900-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T21:53:58Z","timestamp":1742939638000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/5\/1147\/534349\/Long-term-safety-and-efficacy-of-fitusiran"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013900","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}